AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Nanologica

Regulatory Filings Nov 28, 2025

3182_iss_2025-11-28_9877bcbf-6ed0-4833-98f3-939d528777de.pdf

Regulatory Filings

Open in Viewer

Opens in native device viewer

Nanologica AB (publ) Receives Order of SEK 1.5 Million on a New Product

Nanologica has received an order for a non-silica-based purification media from a customer in Asia. The order value amounts to approximately SEK 1.5 million.

"To broaden our portfolio of chromatography media, we have a development program for additional applications. We are at an early stage and are therefore pleased to already receive a larger order. The visibility of revenue on this program is low, but in the long term it has the potential to provide a valuable revenue addition for the company," comments Nanologica's CEO Andreas Bhagwani.

The order is expected to be delivered in the first quarter of next year.

For further information, please contact

Johanna Johansson Director IR, Communications and Marketing [email protected] +46 72 211 21 90

About Nanologica AB (publ)

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica's products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

This information is information that Nanologica AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-11-28 10:21 CET.

Attachments

Nanologica AB (publ) Receives Order of SEK 1.5 Million on a New Product

Talk to a Data Expert

Have a question? We'll get back to you promptly.